Grifols and Endpoint collaborate on sepsis research

Spanish plasma-derived medicines company Grifols (ME: GRF) has entered into a collaboration with Endpoint Health, a US precision-medicine therapeutics company dedicated to addressing urgent needs in immune-driven critical care, to develop and commercialize an antithrombin III (AT-III) therapy to treat sepsis.

As part of the agreement, Grifols will contribute its industry-leading expertise in plasma-protein therapies and be the exclusive supplier of AT-III, a plasma protein that treats patients with blood clotting issues. Grifols will provide up to $25 million to support the clinical development of antithrombin III in sepsis.

Later this year an Investigational New Drug (IND) application will be submitted to the US Food and Drug Administration for a Phase II clinical trial with Grifols’ Antithrombin III. This therapy is the only plasma-protein therapy authorized and approved by the FDA for use in the country to treat Antithrombin III deficiency, an inherited blood-clotting disorder. Grifols has committed to provide up to USD 25 million to support the clinical development program.